Comparative clinical study on Buras and Rohitaka in Liver Disorder

Hepatoprotective activity of Rhododendron arboreum sm.(Pullas)and Tecomela undulatasm.(Rohitak)-A comparative clinicalstudy

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/11/010371

Enrollment

Registered

2017-11-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Elevated AST and ALT more than 40 IU/L levels measured at screening

Interventions

Intervention1: Group B: Stem bark of Rhododendron arboreum churna 3 gm twice a day for 30 days Control Intervention1: Group A: Tecomela undulata Stem bark churna 3 gm twice a day for 30 days

Eligibility

Inclusion criteria

Inclusion criteria: 1. Elevated AST and ALT More than 40 IU/l measured at screening in the study laboratory 3. Readiness to comply with Randomization , treatment and follow up 4. Subject giving written informed consent

Exclusion criteria

Exclusion criteria: 1. Patient with hepatocellular carcinoma, cirrhosis, fulminant hepatitis. 2. Any other serious disease limiting life expectancy 3. Pregnancy and Lactation

Design outcomes

Primary

Measure	Time frame
To Study the efficacy of Rhododendron arboreum and Tecomela undulata wsr to their hepatoprotective action in clinical trialTimepoint: After three months providing the test drugs, count from the day of first dose administration.	—

Secondary

Measure	Time frame
To compare the hepatoprotective action of Rhododendron arboreum and Tecomela undulata in atients of liver diseaseTimepoint: 18 months	—

Countries

India

Contacts

Public ContactDr Sumit Nathani

National Institue of Ayurveda

mita@ayu.in9414078872

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026